Sipurui Pharmaceutical Technology

Sipurui Pharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary platforms focused on protein-protein interactions (PPI) and protein degradation (PROTAC) to address challenging targets in oncology and immunology. Sipurui's pipeline includes several early-stage programs, with a primary focus on ubiquitin-specific proteases and other regulatory proteins involved in cancer progression. Its lead candidate, SPR001, is a potent USP7 inhibitor currently in clinical development for solid tumors. Headquartered in Suzhou BioBAY, the company aims to provide first-in-class or best-in-class treatments for patients with unmet medical needs. Sipurui is supported by a strong network of venture capital investors and academic collaborations.